Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model-Reference-Cited by-同舟云学术

Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model

Published:2009-01-08 Issue:2 Volume:117 Page:305-317
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Lux Michael Patrick,Hartmann M.,Jackisch C.,Raab G.,Schneeweiß A.,Possinger K.,Oyee J.,Harbeck N.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-008-0294-9.pdf

Reference42 articles.

1. Porzsolt F, Klinische Ökonomik (2003) Die ökonomische Bewertung von Gesundheitsleistungen aus der Sicht des Patienten. In: Porzsolt F, Williams AR, Kaplan RM, Klinische Ökonomik (eds) Effektivität und Effizienz von Gesundheitsleistungen. Ecomed, Landsberg, pp 17–40

2. Health and Health Care 2010 (2000) The forecast, the challenge by the Institute for the Future. Jossey-Bass, San Francisco, CA, ISBN 0-7879-5348-2

3. National Institute for Clinical Excellence (NICE) (2008) http://www.nice.org.uk

4. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2008) http://www.iqwig.de/index.2.en.html

5. Federal Ministry of Health (Bundesgesundheitsministerium, BMG FHM (2008) http://www.bmg.bund.de/cln_041/DE/Home/homepage_node.html_nnn=true

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models;PharmacoEconomics;2021-11-29

2. Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer;Breast Care;2021-09-09

3. Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions;PharmacoEconomics;2020-11-26

4. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis;Breast Cancer;2019-12-18

5. German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30;Quality of Life Research;2019-09-04